Prevalence of Undiagnosed Testosterone Deficiency in Aging Athletes: Does Exercise Training Influence the Symptoms of Male Hypogonadism?

2010 ◽  
Vol 7 (7) ◽  
pp. 2591-2601 ◽  
Author(s):  
Luigi Di Luigi ◽  
Paolo Sgrò ◽  
Valentina Fierro ◽  
Serena Bianchini ◽  
Giancarlo Battistini ◽  
...  
Keyword(s):  
Exercise Training ◽  
Male Hypogonadism ◽  
Testosterone Deficiency ◽  
Aging Athletes

scholarly journals Testosterone therapy in men with testosterone deficiency: are the benefits and cardiovascular risks real or imagined?

2016 ◽  
Vol 311 (3) ◽  
pp. R566-R573 ◽  
Author(s):  
Abdulmaged M. Traish
Keyword(s):  
Critical Analysis ◽  
Clinical Evidence ◽  
Medical Condition ◽  
Male Hypogonadism ◽  
Testosterone Deficiency ◽  
Cardiovascular Risks ◽  
Testosterone Therapy ◽  
Beneficial Effects ◽  
Adult Men ◽  
Meta Analyses

In the adult male, testosterone (T) deficiency (TD) also known as male hypogonadism, is a well-established medical condition, which has been recognized for more than a century. T therapy in men with TD was introduced as early as 1940s and was reported to improve overall health with no concomitant serious adverse effects. A wealth of recent studies demonstrated that T therapy in men with TD is associated with increased lean body mass, reduced fat mass and waist circumference, improvement in glycemic control, and reduced obesity. T therapy is also associated with improvements in lipid profiles, amelioration of metabolic syndrome (Met S) components, reduced inflammatory biomarkers, reduced systolic and diastolic blood pressure, and improvements in sexual function. More importantly, T therapy is associated with amelioration of diabetes and reduced mortality. However, few studies, marred with serious methodological and analytical flaws reported between 2010 and 2014, suggested that T therapy is associated with increased cardiovascular (CV) risk. As summarized in this review, a thorough and critical analysis of these studies showed that the risks purported are unsubstantiated and such studies lacked credible scientific and clinical evidence. Moreover, recent observational, registry studies, clinical trials, and meta-analyses, all revealed no increase in CV risks in men receiving T therapy. In this review, the benefits of T therapy in adult men with TD and the lack of credible evidence suggesting that T therapy is linked to increased CV risks are discussed. It should be noted that the literature is replete with studies demonstrating beneficial effects of T therapy on CV and overall health.

scholarly journals Guidelines for the Diagnosis and Treatment of testosterone deficiency (hypogonadism) in male patients

2017 ◽  
Vol 62 (6) ◽  
pp. 78-80 ◽  
Author(s):  
Ivan I. Dedov ◽  
Galina A. Melnichenko ◽  
Roman V. Rozhivanov ◽  
Dmitriy G. Kurbatov
Keyword(s):  
Testosterone Level ◽  
Klinefelter Syndrome ◽  
Kallmann Syndrome ◽  
Diagnosis And Treatment ◽  
Male Hypogonadism ◽  
Androgen Deficiency ◽  
Testosterone Deficiency ◽  
Male Patients ◽  
Clinical Conditions ◽  
Specific Symptoms

Hypogonadism in male patients defined as testosterone level decrease in serum associated with specific symptoms and/or signs (see the detailed description below) can be observed in case of abnormal changes in testes and/or pituitary such as Klinefelter syndrome, Kallmann syndrome and also in male patients with idiopathic, metabolic or iatrogenic disorders resulting in androgen deficiency. The Guidelines does not review all disorders conditioning development of testosterone deficiency (hypogonadism), but focusing on the options of the clinical conditions of hypogonadism generally observed in male patients. This article contains a supplement to the previously published draft of the guidelines: Dedov I.I., Mel’nichenko G.A., Rozhivanov R.V., Kurbatov D.G. The recommendations on diagnostics and treatment of male hypogonadism (deficit of testosterone). The project. Problems of Endocrinology. 2015;61(5):60-71. doi: 10.14341/probl201561560-71

scholarly journals Testosterone replacement therapy in men who conceived with intracytoplasmic sperm injection: nationwide register study

2020 ◽  
Vol 182 (4) ◽  
pp. 423-428 ◽  
Author(s):  
Angel Elenkov ◽  
Yahia Al-Jebari ◽  
Yvonne Lundberg Giwercman ◽  
Aleksander Giwercman
Keyword(s):  
Replacement Therapy ◽  
Intracytoplasmic Sperm Injection ◽  
Testosterone Replacement ◽  
Fertility Treatment ◽  
Testosterone Replacement Therapy ◽  
Male Hypogonadism ◽  
Testosterone Deficiency ◽  
Cox Regression Analysis ◽  
Infertile Men ◽  
Co Morbidity

Objectives Male hypogonadism is associated with higher risk of co-morbidity and premature mortality. It is, therefore, of utmost importance to identify young men who are at the highest risk of testosterone deficiency and who may benefit from preventive measures. In this context, infertile men constitute a high-risk group. The extent of testosterone replacement therapy (TRT) among infertile men, defined as men who have to undergo assisted reproduction for fatherhood, is currently unknown. Therefore, we evaluated the pattern of prescription of TRT in the years following child conception among men who have fathered children with the help of intracytoplasmic sperm injection (ICSI) or in vitro fertilization (IVF). Design By sourcing data from national population registries, hazard ratio (HR) for subsequent TRT was assessed for IVF and ICSI-treated men and compared to those who conceived spontaneously with age Cox regression analysis adjusted for age, educational level and previous intake of medicines for metabolic diseases. Results ICSI and IVF fathers had increased incidence of newly prescribed TRT compared to fathers conceiving spontaneously (ICSI: HR = 3.81, 95% CI = 3.09–4.69, P < 0.001; IVF: HR = 1.54, 95% CI = 1.15–2.05, P = 0.003). After adjustment for prescription of medication for one or more components of the MetS prior to TRT, the risk estimates attenuated but remained robust both for ICSI-treated (HR = 3.17 (95% CI: 2.56–3.9) and IVF-treated men (HR = 1.06 (95% CI: 1.05–1.07). Conclusion Men who have to utilise powerful techniques, such as ICSI for fathering children, may be at risk for testosterone deficiency. Routine endocrine evaluation of men seeking fertility treatment is hence warranted.

scholarly journals HORMONAL AND CLINICAL PROFILE OF HYPOGONADISM IN DIABETES PATIENTS

2019 ◽  
Vol 3 (6) ◽  
Author(s):  
Dr. Dattatray Hambhire
Keyword(s):  
Diabetes Mellitus ◽  
Hypogonadotropic Hypogonadism ◽  
Diabetic Patients ◽  
Male Hypogonadism ◽  
Testosterone Deficiency ◽  
Hypergonadotropic Hypogonadism ◽  
Idiopathic Hypogonadotropic Hypogonadism ◽  
Biochemical Evidence ◽  
Testosterone Levels ◽  
Arm Span

Introduction: Hypogonadism in male is defined as a condition in which there is a clinical characterization of both sign and symptom and biochemical evidence of testosterone deficiency. Male hypogonadism is one kind of recognized medical condition in which these remains under diagnosed by clinicians. A clinical syndrome which consists of with or without signs and associated with biochemical evidence of testosterone deficiency in called Hypogonadism. Over two decades ago, association between the diabetes mellitus (DM) and hypogonadism came to limelight when a high prevalence of low testosterone levels was observed in men with diabetes.  Many studies showed that in one‑third of diabetic men there are low free testosterone levels, which are independent of sex hormone‑binding globulin (SHBG). Due to deficiency of testosterone in men is associated with negative consequences. Many research showed that in DM patients there is increasing evidence of hypogonadism is a risk factor for coronary artery disease, the leading cause of mortality. Other adverse effects are also been reported associated with hypogonadism which included as poor quality of life, sexual dysfunction, increased fracture risk, increasing fat mass, cognitive decline, and mortality. Aim: The main aim of this study is to find out the type of hypogonadism as either hypogonadotropic or hypergonadotropic in DM patients. Material and methods: Total 70 patients were include in this study in which patients visiting out patients department (OPD) of medicine and in patients department (IPD).  Individuals with chronic systemic illness, abuse drugs or alcohol and undergone cancer chemotherapy or radiotherapy were excluded in this study.  Detailed history of the patients was taken from the patients like height, weight and arm span with general and systemic examination to rule out any systemic illness were noted. Estimation of hormonal levels was noted from all patients. Result: Total 80 DM male patients were included in this study. Out of 70 patients 49 (70%) were below 35 years old and remaining 21(30%) were above 36 years old. Out of 70 patients 55 had hypogonadotropic hypogonadism and 15 had hypergonadotropic hypogonadism in male respectively. Out of total patients 55 had hypogonadotropic hypogonadism. Most common etiology was idiopathic hypogonadotropic hypogonadism.  Patient with bilateral anorchia or vanishing testis syndrome, two patients had kallmann syndrome, five of them had hypopituitarism and interestingly three patients had features of gigantism and hypogonadism. 15 patients had hypergonadotropic hypogonadism in which 11 had Klinefelter syndrome and 4 had Turner’s syndrome. Conclusion: The most common cause is Idiopathic hypogonadotropic hypogonadism is shown in male. Height, weight and Arm span varied significantly between Males of hypogonadotropic hypogonadism and hypergonadotropic hypogonadism. Maximum number of patients of DM in India, the incidence of hypogonadism is more in diabetic patients as compared to the general population. Hence, implementation of screening programs in diabetic patients is necessary to understand and detect individuals with low serum total testosterone at any early stage and to supplement testosterone accordingly. Keywords: diabetes mellitus, hypogonadism, testosterone, Hypogonadotropic hypogonadism

Hormonersatztherapie des Mannes

2018 ◽  
Vol 143 (19) ◽  
pp. 1405-1416 ◽  
Author(s):  
Michael Zitzmann
Keyword(s):  
Insulin Resistance ◽  
Mammary Gland ◽  
Chronic Illness ◽  
Replacement Therapy ◽  
Male Hypogonadism ◽  
Testosterone Deficiency ◽  
Emotional Wellbeing ◽  
Inflammatory Conditions ◽  
Natural Hormone ◽  
Multiple Morbidities

AbstractTestosterone is a natural hormone which is essential to maintain physical and emotional wellbeing in men. Male hypogonadism is an endocrine condition of testosterone deficiency with the potential to cause multiple morbidities and psychosocial complaints. The condition can be of primary (testicular), secondary (hypothalamic-pituitary) or so-called functional origin (as a result of inflammatory conditions, obesity or chronic illness). Testosterone deficiency can cause symptoms of sexual nature, insulin resistance, osteoporosis, anemia among others. A replacement of testosterone should not be initiated in case of desired paternity, unclear processes of the prostate, mammary gland, or high hematocrit. Diagnosis and treatment as well as surveillance of the therapy of hypogonadism are clearly regulated by international guidelines and replacement therapy is proven to be effective to ameliorate the above-named complaints when performed according to these guidelines.

Testosterone Deficiency or Male Hypogonadism

2012 ◽  
pp. 213-238
Author(s):  
Christian A. Koch ◽  
Michael Zitzmann
Keyword(s):  
Male Hypogonadism ◽  
Testosterone Deficiency

scholarly journals The consensus recommendations of a group of international experts on the fundamental concepts related to the issues of testosterone deficiency and its treatment.

2016 ◽  
Vol 13 (3) ◽  
pp. 15-31
Author(s):  
Abraham Morgentaler ◽  
M. Zitzmann ◽  
A. M. Traish ◽  
A. W. Fox ◽  
T. H. Jones ◽  
...  
Keyword(s):  
Disease Risk ◽  
Medical Condition ◽  
Cardiovascular Disease Risk ◽  
Well Being ◽  
Male Hypogonadism ◽  
Testosterone Deficiency ◽  
Testosterone Therapy ◽  
Medical Specialties ◽  
Beneficial Effects ◽  
Research Initiative

Conference on the development of the international expert consensus to address frequently asked questions related to a medical condition of testosterone deficiency (TD, male hypogonadism) and testosterone therapy was held in Prague (Czech Republic) on October 1, 2015. The included experts were representatives from a variety of medical specialties, including urology, endocrinology, diabetology, internal medicine, as well as representatives of basic medical sciences. An international team of experts came to the following conclusions: TD - an important medical condition that affects the health and well-being of men; TD symptoms is a consequence of low testosterone levels, regardless of whether background etiology installed; TD consequences are global; care must be taken in an attempt to use any uniform threshold levels of testosterone for a decision on the appointment of testosterone therapy; a person does not have any reason to refrain from appointing testosterone therapy only on the basis of age; the existing evidence does not suggest increasing the prostate cancer or cardiovascular disease risk during testosterone therapy; there is evidence conserning the feasibility of a major research initiative to explore possible cardioprotective beneficial effects of testosterone therapy in men with metabolic disorders, including diabetes.

Sign in / Sign up

Export Citation Format

Share Document